It has become one of the defining stories in Healthcare Technology — and it is reshaping how the sector operates worldwide. Sweekly spoke with executives, engineers and investors to understand what is really driving the shift, and what it means for the businesses that will live with the consequences.
The regulatory path under the new EU framework is longer, and companies have adjusted their timelines accordingly.
The evidence
Evidence from multi-site trials is finally catching up to the marketing claims.
Keeping patients monitored at home is where the clearest cost savings appear.
“Technology was the easy 20 percent. Reimbursement is the other 80.”— Co-founder
The technology
The data infrastructure behind precision medicine is as important as any single device.
Reimbursement, not technology, is the gate most digital-health products fail to clear.
What to watch
- Evidence from independent, multi-site clinical trials
- A clear regulatory path under the new EU rules
- Reimbursement pathways that make adoption viable
- Interoperability with existing hospital systems
The clinical case
Clinicians are cautious adopters, and rightly so — trust is earned slowly here.
Point-of-care diagnostics compress days of waiting into minutes.
What comes next
In the clinic, the system reads scans alongside radiologists, flagging what the eye might miss.
The regulatory path under the new EU framework is longer, and companies have adjusted their timelines accordingly.
The bottom line
Keeping patients monitored at home is where the clearest cost savings appear.
Sources & further reading
Written by
Nora SundqvistHealthcare Tech Correspondent
Nora reports on the devices and platforms changing how care is delivered.
Discussion(3)
Excellent analysis. The point about permitting timelines really is the crux of the whole thing.
Great reporting as always from the Sweekly desk. The data on adoption is eye-opening.
Great reporting as always from the Sweekly desk. The data on adoption is eye-opening.